• The elbows, knees, legs, lower back, scalp, and glans penis are the sites most often affected.
Nails
Nail involvement is common and can present as:
• pitting
• separation of the distal nail plate from the nail bed (onycholysis)
• pinkish-brown flecks beneath the nail plate ('oil spots')
• subungual hyperkeratosis.
Acrodermatitis continua of Hallopeau is a painful, localised, pustular form of psoriasis which often leads to nail deformity.
Joints
Psoriasis may also affect the joints in 5 -10% of cases. (Table II) • Plaque psoriasis accounts for 80 -90% of cases. 12 It is a stationary form of the disease with the lesions often covered with thick, silvery or waxy scales. Patients may have involvement ranging from only a few plaques to numerous lesions covering almost the entire body surface. 13 • Guttate psoriasis is often triggered by tonsillitis. Its small lesions are widely distributed over the body.
Common types of psoriasis
• Flexural (inverse) psoriasis is localised to the main skin folds (genitocrural area, navel, axillae, submammary region).
• Pustular psoriasis may be generalised or localised to the palms and soles.
• Erythrodermic psoriasis is a generalised form of the disease and is most refractory to treatment. (Table III) 
Differential diagnosis

Scalp
• Seborrhoeic dermatitis. The flakes are thinner and 'greasier', and the condition responds better to treatment. It is often difficult to differentiate seborrhoeic dermatitis from psoriasis unless other skin areas offer additional information.
• Fungal infection of the scalp mostly affects children. This diagnosis can be excluded by microscopy and a negative culture for fungi.
• Neurodermatitis of the neck (lichen simplex nuchae) is characterised by an isolated, lichenified, pruritic plaque covered with thin scales.
Flexures
• Seborrhoeic dermatitis may resemble flexural psoriasis.
Other skin areas should be examined. • Candidiasis is not often seen in young and middle-aged patients. It presents as a moist area of erythema and maceration with outlying 'satellite lesions'.
• Erythrasma is a macular brown area with few symptoms, most often found in the axillae or groin. It is caused by an overgrowth of diphtheroids, which are part of the normal skin flora. These areas fluoresce coral-pink under Wood's light.
Hands, feet
• Hyperkeratotic eczema of the palms and palmoplantar pustulosis may be difficult to differentiate from psoriasis. The entire skin should be examined.
• Fungal infection can easily be diagnosed by microscopic examination and culture.
Classification
Classification of psoriasis is based on the type of psoriasis (see above) and on disease severity, which is described as mild, moderate or severe.
Severity is a qualitative decision, hinging on the measures of disease activity, resistance to prior therapy and psychosocial considerations. Various measures of severity exist and are listed in Table IV. A 75% improvement in the PASI score (PASI-75) is predominantly used to document the effectiveness of individual therapies in clinical trials of patients with extensive psoriasis. 13 A DLQI of 10 or more correlates well with severe disease requiring admission, phototherapy or second-line therapy, and an improvement in DLQI of 5 or more points is considered a worthwhile criterion for response.
One should keep in mind that marked cross-cultural inequivalence exists in these tools to measure quality of life impact; 12 no tools for this purpose have been developed specifically for South African cultural groups.
Quality of life
Psoriasis may profoundly affect all aspects of patients' social and personal lives (including their work). The impact of psoriasis on a patient is not directly related to the overall area affected, or to other parameters of disease activity such as redness or thickness of plaques, but more to the site distribution and the attitude of the patient. It is important to be able to measure the handicap caused by psoriasis for use in clinical trials, for audit purposes and to aid clinical decision taking.
How do we define the severity of psoriasis?
All existing disease severity assessment tools are imperfect and most require some training to complete. There is currently no universally accepted definition of what constitutes mild, moderate and severe psoriasis, nor can there be a concise and clinically meaningful definition given the broad clinical spectrum.
BSA of involvement is not an adequate parameter. The PASI score, severity of individual lesions, localisation of lesions, symptoms, functional impairment, effect on quality of life of the patient, and response to and side-effects of previous treatment also have to be taken into account.
The Working Group considered the existing definitions [14] [15] [16] [17] [18] of moderate to severe psoriasis and concluded that the burden psoriasis presents to the patient is often underestimated by physicians and regulatory authorities, as is the extent to which current treatments influence patients' quality of life.
The Working Group made recommendations for the defining criteria of psoriasis severity (Table V) .
Referral (Table VI)
Referral to a dermatologist should be considered in the following instances:
• Patients with extensive disease who need secondary care treatments. The dermatologist should also be involved in the care of difficult cases where the site or unresponsiveness of the rash are important factors.
• Diagnostic uncertainty.
• Request for further counselling and/or education, including demonstration of topical treatment.
• Failure of appropriately used topical treatment for a reasonable time (e.g. 2 -3 months).
• Extensive disease, if unresponsive to initial therapy or difficult to self-manage.
• Need for increasing amounts or potencies of topical corticosteroids.
• Involvement of sites which are difficult to treat, e.g. face, palms and soles, genitalia, if unresponsive to initial therapy.
• Need for systemic therapy, phototherapy (e.g. guttate psoriasis), day treatment or inpatient admission.
• Generalised erythrodermic or generalised pustular psoriasis (emergency referral is indicated), or acute unstable psoriasis (urgent referral may be justified).
• Adverse reactions to topical treatment.
• Occupational disability or excessive time off work or school.
Content of the referral letter (Table VII)
The referral letter should include:
• The reason for referral and what is hoped to be gained from the consultation (the consultant should try to address these issues in reply).
• The patient's present therapy (if any), its duration and the quantity being used. • Psoriasis Area and Severity Index (PASI). The PASI is a measure of overall psoriasis severity and coverage that assesses body surface area, erythema, induration and scaling
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• Body surface area (BSA) affected • Overall Lesion Severity Scale (OLS) • Physician's Global Assessment (PGA)
• Health-related Quality of Life (HRQL)
• Dermatology Life Quality Index (DLQI)
• Information on previous therapy, including responses or side-effects (a treatment could be mistakenly recorded as ineffective when the real problem was under-treatment or incorrect use of the prescribed treatment, or discontinued as unsuitable when transient side-effects could have been overcome had more advice been given).
• Any relevant background information, including the patient's general health and current medication.
• The patient's home circumstances. This is important as the patient's ability to apply topical therapies at affected sites may be compromised, affecting treatment choice.
What is the current treatment paradigm?
Treatment paradigms are conventionally based on the morphological type and severity of psoriasis.
For moderate to severe plaque psoriasis, many practitioners believe in the traditional strategy, commonly depicted as a stepwise paradigm starting with topical agents followed by phototherapy and then systemic agents. 10, 11, 16 The physician must deem a step ineffective before progressing to the next step.
First-line systemic treatment may be indicated if topical therapy is impractical. 1 More recent versions of the stepwise model (Table VIII) incorporate biologicals into the same category as other systemic agents and recommend that they be considered as first-line therapies alongside conventional systemic agents. 
Shortcomings of the conventional treatment paradigm
The Working Group considered both the shortcomings of the stepwise treatment paradigm and potential areas for improving the current recommendations for the care of patients, and concluded that there was an unmet need in the management of moderate to severe psoriasis.
The therapy(ies) selected by the patient with the advice of their physician must take into account the following aspects:
Disease
• The type of psoriasis present in the patient • Location of lesions: face, ears, hands, feet, genitalia and intertriginous areas, scalp, nails, trunk, extremities
• Severity of the lesions: thickness, redness, scaling
• Symptoms: pain, pruritus, other
• Extent of disease, BSA estimates; PASI score
• Joint involvement.
Patient
• Age of the patient
• Quality of life considerations: ability to perform daily activities, employability, interpersonal relationships
• Co-morbid disease/disease states including childbearing potential, pregnancy, desire to impregnate, liver disease, hepatitis C or HIV infection, hypertension, metabolic syndrome and alcohol intake.
Treatment
• Response to previous therapies
• Accessibility to dermatologist, hospital, ultraviolet (UV) light facilities
• Therapies available to treating physician, and physician preferences and experience. Step 1
Step 2
Step 3 6.2 What are the unmet needs for treatment of patients with moderate to severe psoriasis? (Table  IX) There is a need for improved education on the negative physical and HRQL impact on patients and physicians (e.g. physical, emotional and social impact). To help patients come to terms with what is, for many, a lifelong condition, great efforts should be made to improve communication during consultations and to educate patients.
Patients should have a plan of management, including the therapeutic options for the treatment of their psoriasis at each site involved, and verbal and written information on the probable benefits and possible side-effects of each therapy, enabling them to make an informed decision about the treatment.
Ideally practical demonstrations of the application of treatment should be offered by appropriately trained members of a primary health care team.
An introduction to patient support groups may be helpful.
Current therapeutic options
Therapeutic options for psoriasis range from topical treatment to phototherapy and systemic agents, including biologicals (Fig. 1) . The choice of therapy is determined in part by the severity of the illness. Each of these therapeutic options will be discussed in depth, highlighting the current evidence supporting their efficacy and safety, their practicality for patient and physician, and general recommendations for their use. 13, 32, 33 The various therapeutic options will now be discussed by treatment class. This section of the guidelines has been adapted with written permission from the authors of the German Guidelines for Psoriasis. 32, 33 
Topical therapy
Evidence has shown that the selection of treatment for patients with psoriasis vulgaris is more commonly based on traditional concepts than evidence-based data on the efficacy of various therapeutic options. This section of the guidelines provides explanations of available topical treatments, as well as different photo-and photochemical therapies, for psoriasis. They are based on the German evidence-based guidelines for the treatment of psoriasis vulgaris, modified and adapted where applicable for the South African context. 32, 33 The aim of the guideline is to provide a tool that enables the physician to select an appropriate treatment for each individual patient on the basis of evidence-based studies rather than personal experience or traditional therapeutic concepts. For this purpose a total of 6 224 publications were evaluated and data used where appropriate.
The currently available topical treatments are summarised in Table X , which provides an overview of the evaluation of therapeutic options. The various therapeutic options are then discussed in more detail. (Table XI) 33
Topical corticosteroids
General assessment
With the application of potent corticosteroids (betamethasone diproprionate, twice daily), 46 -56% of patients show a clear improvement or a complete clearing of skin lesions. Therapy with very potent corticosteroids (clobetasol-17-propionate, twice daily) demonstrated similar results in 68 -89% of patients in most studies.
Topical corticosteroids demonstrate good to very good efficacy in the treatment of mild to moderate psoriasis. Combination with salicylic acid enhances the therapeutic effect. Combination with other systemic or topical therapies also results in improved rates of remission. The most common combination is with topical vitamin D 3 derivates or tar.
There are no severe adverse drug reactions in the induction phase. Care must be taken regarding development of typical adverse corticosteroid effects such as skin atrophy or telangiectasia in cases of longer use and in particularly sensitive areas. The practicality for physicians and patients is good. (Table XII) 33
Coal tar
General assessment
Since only one monotherapy study was evaluated (with 3 patients), it is not possible to make a clear statement about the efficacy of monotherapy (level of evidence (LE) 4). Coal tar has been used in clinical studies in combination with phototherapy.
In combination therapy with UV light, a reduction of the PASI by about 75% was achieved in 45 -80% of study participants after 15 -20 applications. The additional effect of coal tar in combination therapy with UV compared with UV therapy alone has not been proven.
Therapeutic recommendation
• Therapy with topical corticosteroids is highly recommended for mild to moderate psoriasis vulgaris as a combination therapy with systemic therapies or other topical therapies.
• The selection of the class of corticosteroids must be adjusted for the specific skin area to be treated.
• Long-term use must take safety aspects into account. • Safe and convenient control 11, [22] [23] [24] [25] [26] [27] • Individualised treatment tailored to patients' needs 1, 19, 28 • Patient satisfaction with current therapy
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• Increased recognition of HRQL issues 30, 31 • Improved education on psoriasis 7.1.3 Dithranol (Table XIII) 33
General assessment
The results of the studies assessed showed total remission (PASI reduction 100%) in 30 -70% of patients and partial remission (PASI reduction 75%) in 26 -100% after 5 -8 weeks of treatment (LE 2). The efficacy can be improved further if either calcipotriol creams or UVB phototherapy are combined with dithranol.
Therapeutic recommendation
• Although the efficacy of coal tar in the treatment of psoriasis as monotherapy has not been demonstrated, it is an inexpensive alternative in some patients.
• It can also be used in combination with phototherapy (UVB).
• Short-duration therapy should be given preference because it is more practical.
• In hospitalised patients, classic dithranol therapy with twice-daily application without immediate rinsing can easily be performed.
• The therapy should be performed for 4 weeks and conditionally recommended as an outpatient treatment for 4 -8 weeks.
• Maintenance or long-term therapy with dithranol is not practical and offers no advantages.
• In the treatment of severe forms of psoriasis, combination treatment with phototherapy or other topical preparations (calcipotriol) is recommended because of the improved response rate. 
Efficacy. The evaluation of the efficacy column reflects the percentage of patients who achieved a reduction in the baseline Psoriasis Area and Severity Index (PASI) of ≥75% (++++ approx. 60%; +++ approx. 45%; ++ approx. 30%; + approx. 15%; +/-approx. 10%; -not defined).
The evidence level applies only to the estimate of efficacy.
Safety/tolerance on induction therapy or maintenance therapy. This refers to the risk of occurrence of severe adverse drug reactions or the probability of adverse drug reactions that would result in the discontinuation of therapy.
Practicality (patient).
This evaluation analyses the effort involved in handling and administrating the treatment regimen by the patient.
Practicality (physician).
This aspect considers the amount of work (documentation, explanation, monitoring), personnel and equipment needs, time for physician/patient interaction, remuneration of therapeutic measures, invoicing difficulties/risk of recourse claims from the health insurance companies.
Cost/benefit. Consideration for the costs of an induction therapy, or a maintenance therapy.
The evaluations of safety/tolerance in induction therapy or maintenance therapy as well as practicality for the physician or patient and the cost/benefit were performed using a scale ranging from poor (-) to good (++++). The gradation between these two extremes was made based on expert opinion and unsystematic literature search. A level of evidence was not given for these evaluations, since no systematic literature review was performed. 
Guideline
April 2010, Vol. 100, No. 4 SAMJ Dithranol, one of the oldest topical therapeutics for psoriasis, is still a treatment for mild to moderate psoriasis as outpatient monotherapy and as part of combination therapies for moderate psoriasis in hospitalised and day clinic patients.
The therapy is very safe. Although skin irritation, burning, erythema and intermittent brown discolorations are observed, there are no systemic adverse reactions. The practicality is limited in outpatient use, due to these events, and the introduction of newer topical agents. However, the practicality for the physician, especially when treating inpatients, and the cost/benefit ratio are positive. (Table XIV) 33
Tazarotene
General assessment
After daily treatment with tazarotene 0.1%, approximately 50% of patients showed at least a 50% improvement of the skin lesions after about 12 weeks of treatment (LE 2). Therapeutic success and reduction of the frequent skin irritations can be optimised with a combination of tazarotene and topical corticosteroids. There are no severe adverse reactions. However, contact with healthy skin should be avoided to prevent skin irritation. (Table XV) 33
Vitamin D 3 analogues
General assessment
The majority of available data are on calcipotriol. After D 3 -analogue treatment of mild to moderate psoriasis, 30 -50% Avoid concomitant use of preparations with irritating and drying properties
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Therapeutic recommendation
• The topical application of tazarotene is recommended for the treatment of mild to moderate psoriasis.
• An application of tazarotene in the evening in combination with a corticosteroid in the morning is recommended as a combination therapy to reduce irritation and increase efficacy.
of patients showed a marked improvement or clearance of the skin lesions within a few weeks (LE 1).
Efficacy and tolerance can be improved further if the vitamin D 3 analogue is combined with topical corticosteroids during the initial therapy. In the treatment of severely affected patients, topical therapy with vitamin D 3 analogues demonstrated synergistic effects with UV phototherapy and systemic ciclosporin therapy.
The topical vitamin D 3 analogues are generally well tolerated and practical for the physician and the patient. Temporary skin irritation may limit use, especially on the face or the intertriginous areas.
Tacrolimus ointment
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• Tacrolimus ointment is effective for facial and intertriginous psoriasis.
• Topical tacrolimus appears relatively ineffective for the treatment of plaque-type psoriasis owing to poor penetration through the plaque.
• A thin layer of cream is applied to the affected areas twice a day.
• It is well tolerated and the only adverse effect is occasional pruritus in the treated areas.
• Topical tacrolimus offers the potential for anti-inflammatory effect without the atrophy or local side-effects associated with the use of topical corticosteroids.
• It is therefore recommended for use in intertriginous or facial psoriasis.
Phototherapy (Tables XVI and XVII) General assessment
About three-quarters of all patients treated with phototherapy attained at least a 75% PASI score reduction after 4 -6 weeks, and clearance was frequently achieved (LE 2). Phototherapy represents a safe and very effective modality for the treatment of moderate to severe forms of psoriasis. The onset of the clinical effect is within 2 weeks.
Of the unwanted side-effects, UV erythema from overexposure is by far the most common and is frequently observed. With repeated or long-term application, the consequences of high, cumulative UV dosages (i.e. premature ageing of the skin) must be taken into consideration. In addition, carcinogenic risk is associated with oral psoralen + UVA photochemotherapy (PUVA) and is probable for local PUVA and UVB.
The practicality of the therapy is limited as a result of the spatial, financial and human aspects, as well as the amount of time required by both the physician and the patient. From the perspective of the cost-bearing institution, phototherapy has a good cost-benefit ratio. However, the potentially significant costs and time required of the patient must be noted.
Instructions for application
Pre-treatment
• The attending physician has to perform a complete skin 
Therapeutic recommendation
• Vitamin D 3 analogues are the treatment of choice for maintenance therapy in mild to moderate psoriasis.
• On the basis of the extensive study data and superior efficacy, this recommendation is particularly true for calcipotriol.
• The application of tacalcitol is particularly recommended for sensitive areas (e.g. face), owing to its low irritation potential.
• In the first weeks, combined use together with topical corticosteroids or as a fixed combination is superior to monotherapy with respect to efficacy and tolerance.
• For moderate to severe psoriasis, a combination of topical vitamin D 3 analogues with UV phototherapy or as systemic therapy can be recommended.
examination, paying special attention to melanocytic naevi (especially if dysplastic) and cutaneous malignancies.
• The patient must be informed about unwanted side-effects and possible long-term risks -especially the therapy-related increased risk of skin cancer. Additional UV exposure as a result of leisure-time activities should be considered.
• Before starting oral PUVA therapy, an ophthalmological examination and the prescription of UV sunglasses is required.
During treatment
• The UV dosages applied must be documented in precise physical units (J/cm 2 or mJ/cm 2 ). Regular monitoring of UV erythema must be performed for the purpose of dosage increases.
• The medical records should document therapeutic response, unwanted side-effects, and accompanying treatments.
• Eye protection with UV glasses is generally required.
• If the areas chronically exposed to light (face, neck, backs of hands) and the genital region are free of lesions, these should be protected from exposure.
• Adequate protection from the sun must accompany therapy.
Post-treatment
• Whenever a course of therapy is completed, the cumulative UV dosage and the number of treatments should be recorded and the patient informed.
• Particularly in the case of patients with high cumulative UV dosage, regular skin cancer examinations should be performed for the rest of the patient's life. Global consideration: 
Excimer laser
• Excimer laser is recommended for the targeted treatment of individual psoriatic plaques only.
• The 308 nm excimer laser can be administered to precisely targeted diseased skin, leaving healthy skin unexposed.
• The cumulative UVB dosage is therefore lower than conventional UV treatment.
• Practicality is limited as a result of financial aspects as well as time resources on the part of the patient and physician.
Systemic therapy
The recommendations in these guidelines will be presented according to the level of evidence (Table XVIII) and grade of recommendation (Table XIX) currently available for each systemic agent. The symbols used to indicate these are explained in the above tables. 
Acitretin (oral retinoids) (
Evidence of efficacy
Plaque psoriasis
A systematic review 36 revealed 11 randomised controlled trials (RCTs) in which acitretin was used to induce remission and/or remission maintenance for psoriasis. The heterogeneous nature of the data made data pooling and analysis difficult. Despite its teratogenicity and the high incidence of symptomatic mucocutaneous side-effects, it was moderately effective as monotherapy at doses of 1 mg/kg/d (75 mg/d) compared with placebo, but was less effective than ciclosporin. Used in combination with PUVA, acitretin was more effective than monotherapy. There was insufficient evidence on the use of retinoids as long-term maintenance therapy.
A later evidence-based review 37 included 5 reports on acitretin as monotherapy and confirmed that acitretin was superior to placebo at 1 mg/kg/d (75 mg/d), but 2 RCTs involving 286 people indicated that retinoids were less effective than ciclosporin at inducing remission in 10 -12 weeks. Combination therapies were more effective than monotherapy. In combination with PUVA (6 series; N=286) acitretin combined 
1++
High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with very low risk of bias 1+
Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with low risk of bias 1-Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias 2++
High-quality systematic reviews of case-control or cohort studies; high-quality case-control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal 2+
Well-conducted case-control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal 2-Case-control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal 3
Non-analytical studies, e.g. case reports, case series 4 Expert opinion Table XIX . Grades of recommendation A At least one meta-analysis, systematic review or RCT rated as 1++ and directly applicable to the target population; or a systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating overall consistency of results B A body of evidence including studies rated as 2++, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+ C A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++ D Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+ 0
Not recommendable
Therapeutic recommendation
• Phototherapy is recommended as an induction therapy for moderate to severe psoriasis, particularly for widespread involvement.
• The side-effects of specific types of radiation must be weighed up. A possible subsequent risk of skin cancer is better documented for PUVA than for UVB.
• Practicality and the association of long-term unwanted side-effects with cumulative UV doses must be taken into account in long-term treatment. Combination with topical vitamin D 3 analogues is recommended to improve the response rate.
• A recommendation for the common combination with tar, dithranol and corticosteroids can only be given on the basis of clinical experience, but not on the basis of scientific data.
with PUVA (rePUVA) was marginally more effective than PUVA alone, and there was a trend for a lower accumulative UVA dose with the combination. Similar findings were shown for the UVB combination (3 RCTs; N=149) compared with UVB alone. In combination with topical corticosteroids (2 series; N=160) and topical calcipotriol (2 studies; N=221), the combination was more effective than monotherapy with acitretin.
The German evidence-based guidelines 33 had only 4 studies meeting inclusion criteria for monotherapy and 4 studies for combination therapy. They concluded that the evidence for the effectiveness of acitretin as combination or monotherapy was poor owing to heterogeneous study results and do not recommend its routine use.
Retinoids may be less effective than other systemic agents as monotherapy for short-term management of moderate to severe chronic plaque psoriasis, but they are effectively used in combination with phototherapy and topical agents or for longterm maintenance of clearance induced with other agents. 35, 38 Clinical data suggest that retinoids are effective for erythrodermic psoriasis control. 35, 38, 39 Acitretin should be considered for those patients with co-morbidities contraindicating immunosuppression, such as cancer and HIV co-infection, as it is not an immunosuppressant. 35 
Pustular psoriasis
A systematic review of chronic palmoplantar pustulosis interventions found established but modest evidence to support the use of oral retinoid monotherapy for the induction and maintenance of remission. Efficacy was equal to that of oral PUVA. Combined oral retinoid and PUVA (rePUVA) was more effective than either intervention used alone. 40 
Psoriatic arthropathy
Effectiveness for psoriatic arthritis, compared with placebo, has been shown in one small trial summarised in a systematic review.
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Adverse effects
Acitretin use is associated with a large number of side-effects and toxicity reactions (Table XX) . Compared with other systemic interventions for severe psoriasis, the potential for serious harm appears to be less. 35, 38, 39 
Evidence of efficacy
Plaque psoriasis
A systematic review 36 included 18 RCTs for ciclosporin remission induction efficacy (13 reports) and maintenance of remission efficacy (5 reports) for severe plaque psoriasis. The data were too heterogeneous for pooling (severity, dose, success criteria and duration of treatment), but favoured ciclosporin over placebo. Optimal remission induction responses were found for doses of 2.5 -5.0 mg/kg/d, but higher doses, although more efficacious, were associated with more side-effects. The formulation (Sandimmun® v. Neoral®) did not affect efficacy in the long term, but the emulsion produced a more rapid initial response. Doses of 3.0 -3.5 mg/kg/d given continuously were needed for maintenance of remission. Comparative studies showed that low-dose ciclosporin was more effective than low-dose retinoids. Combined with calcipotriol, efficacy was enhanced.
A later systematic review 43 included an additional RCT comparing ciclosporin and methotrexate as a monotherapy for moderate to severe plaque psoriasis, which is reviewed below.
Recently published RCTs have compared monotherapy ciclosporin with methotrexate [44] [45] [46] in moderate to severe plaque
Therapeutic recommendation
• Despite the poor recommendation as short-term monotherapy for chronic plaque psoriasis remission induction, acitretin is effective when used in combination with phototherapy and topical agents, or for the longterm maintenance of remission/clearance induced by other systemic agents.
• Acitretin is effective for the pustular and erythrodermic variants of psoriasis.
• Acitretin may be effective for psoriatic arthritis.
• Acitretin should be considered for those patients with co-morbidities where immunosuppression is contraindicated, such as those with cancer and HIV co-infection, as it is not an immunosuppressant.
• Acitretin is a teratogen and is not recommended for women of childbearing age. Because of its long half-life, contraception must be used for a minimum of 2 years after stopping acitretin use, and no blood donations are possible for this time period either. 44 In contrast, there was no difference in efficacy, tolerability, rate of remission, time to remission or quality of life score in a study from the Netherlands (N=88). Both ciclosporin (3 -5 mg/kg/d) and methotrexate (15 -22.5 mg/wk given as 3 doses every 12 hours) over 16 weeks resulted in a reduction in psoriasis severity index from baseline of ≥75% (PASI-75) in more than 60% of the patients. 45 In contrast, a study from Sweden (N=84) showed a 72% reduction in PASI (PASI-75 = 58%) for ciclosporin (3 -5 mg/kg/d) compared with a 58% reduction in PASI (PASI-75 = 24%) for methotrexate (7.5 -15 mg/wk given as 3 doses every 12 hours with folate 5 mg/d on non-treatment days) over 12 weeks. There was no difference in quality of life and side-effects were common but tolerable. Although both drugs were effective, ciclosporin was more effective in the short-term treatment of moderate to severe chronic plaque psoriasis. 46 The German guidelines 33 had 15 studies meeting inclusion criteria for monotherapy. They concluded that there is good evidence and an acceptable risk/benefit ratio for ciclosporin as effective monotherapy for remission induction of moderate to severe plaque psoriasis, but advised caution with long-term use because of the renal side-effects.
A systematic review and meta-analysis of RCTs evaluating the efficacy (PASI-75) and tolerability (overall rate of withdrawal) of systemic treatments for moderate to severe psoriasis from Europe and North America, found 9 trials for ciclosporin meeting inclusion criteria. 47 The response (PASI-75) ranged from 25% to 97%, and the variability was only partly explained by variable dosing. Open-label studies had more patients reaching PASI-75 than did double-blind placebocontrolled trials. Ciclosporin (71.4% PASI-75) was more effective than methotrexate (60.5% PASI-75) after 16 weeks of treatment. Long-term efficacy (stable responses for >10 months) was reported in only one study. Owing to heterogeneity associated with an overestimation of efficacy in open-label studies, only double-blind placebo-controlled trials (3/9) of ciclosporin were included in the meta-analysis of 16 studies for biologicals. Ciclosporin (absolute risk difference (RD) 33%, 95% confidence interval (CI) 13 -52%) was less effective than infliximab (RD 77%, 95% CI 72 -81%), adalimumab (RD 64%, 95% CI 61 -68%) and high-dose (50 mg twice weekly) etanercept (RD 44%, 95% CI 40 -48%), but equivalent to or better than low-dose (25 mg twice weekly) etanercept (RD 30%, 95% CI 25 -35%) and efalizumab (RD 24%, 95% CI 19 -30%). Tolerability of ciclosporin was equivalent to the biologicals but better than methotrexate.
Pustular psoriasis
A systematic review of chronic palmoplantar pustulosis interventions found 2 trials for ciclosporin. 40 Despite heterogeneous data, the authors concluded that there was good evidence for improvement, but not clearance, with short-term, low-dose ciclosporin use.
Psoriatic arthropathy
In a systematic review of psoriatic arthropathy interventions, no RCTs were available to evaluate the use of ciclosporin. 41 
Adverse effects
Ciclosporin is metabolised in the liver, so bio-availability and plasma levels are altered by drugs affecting the cytochrome P450 3A enzyme system. Ciclosporin use is associated with a large number of sideeffects and toxicity reactions because of its narrow therapeutic index, low threshold for toxicity and plasma levels which are easily affected by inducers, inhibitors and substrates of cytochrome P450 3A. 33, 36, 38, 42, 43 The incidence and severity of side-effects seen in patients with psoriasis correlates with the cumulative dose and/or duration of use. ), a folic acid antagonist, is an anti-metabolite, which inhibits dihydrofolate reductase preventing nucleotide synthesis, nucleic acid synthesis and hence cell proliferation. Its mechanism of action in psoriasis is unknown. It was thought to have a direct effect on keratinocyte proliferation, but current views link it to T-cell function. It is hepatotoxic, myelosuppressant and teratogenic. 35 
Evidence of efficacy
Plaque psoriasis
A systematic review 36 revealed no randomised controlled trials (RCTs) in which methotrexate efficacy could be evaluated, despite its widespread use and supporting published studies suggesting a significant effect. A later systematic review of treatments for moderate and severe plaque psoriasis 43 included 2 RCTs for methotrexate as monotherapy, which are reviewed below. Published RCTs have compared methotrexate with ciclosporin 44 -46 or adalimumab 49 and placebo 41, 49 in moderate to severe plaque psoriasis.
Therapeutic recommendation
• Ciclosporin is effective remission induction therapy for all types of psoriasis.
• Ciclosporin has equivalent but varying efficacy compared with methotrexate, dependent on the population and dose studied and the use of folate supplementation.
• Ciclosporin has been shown to be effective for moderate to severe plaque psoriasis when used at doses of 2.5 -5 mg/kg/d.
• Ciclosporin improves but does not clear palmoplantar pustulosis.
• Common use confirms its effectiveness for psoriatic arthritis.
• Ciclosporin use is limited by the side-effect, drug interaction and contraindication profiles and monitoring required while on use.
Both methotrexate (0.5 mg/kg/wk) and ciclosporin (3 -4 mg/kg/d) were found to be effective in a study from India (N=30), but methotrexate appeared to produce a more rapid and complete clearance. Side-effects were transient and minor. 44 In contrast, there was no difference in efficacy, tolerability, rate of remission, time to remission or quality of life score in a study from the Netherlands (N=88). Both methotrexate (15 -22.5 mg/wk given as 3 doses every 12 hours) and ciclosporin (3 -5 mg/kg/d) over 16 weeks resulted in a reduction in psoriasis severity index from baseline of ≥75% (PASI ≥75) in more than 60% of the patients. 45 A study from Sweden (N=68) showed a 58% reduction in PASI (PASI-75 = 24%) for methotrexate (7.5 -15 mg/wk given as 3 doses every 12 hours with folate 5 mg/d on non-treatment days), compared with a 72% reduction (PASI-75 = 58%) for ciclosporin (3 -5 mg/kg/d) over 12 weeks. There was no difference in quality of life and side-effects were common but tolerable. Although both drugs were effective, ciclosporin was more effective in the short-term treatment of moderate to severe chronic plaque psoriasis. 46 In an international randomised, double-blind, doubledummy, placebo-controlled study (Canadian and European cohort N=271), a patient response rate of PASI-75 was achieved in 79.6% of patients given adalimumab (80 mg subcutaneously week 0 then 40 mg every 2 weeks), 35 .5% of those given methotrexate (7.5 -25 mg/week orally) and 18.9% of those receiving placebo for 16 weeks. All patients received 5 mg folate weekly, 48 hours after oral medication (CHAMPION study). 49 Methotrexate dose, treatment duration and the use of folate could explain the different responses recorded above.
Placebo comparisons include the CHAMPION study 49 and an RCT of methotrexate use for psoriatic arthritis. 41 In 37 patients receiving methotrexate (7.5 -15 mg/wk orally) or placebo for 12 weeks, a reduction in psoriasis surface area was noted for methotrexate compared with placebo.
The German guidelines 33 had only 3 studies meeting inclusion criteria for monotherapy. They concluded that methotrexate as monotherapy was effective for moderate to severe plaque psoriasis despite the lack of definitive studies, but its use was limited by the controls needed during therapy and contraindications. It was not recommended for remission induction owing to its slow onset of action.
Pustular psoriasis
A systematic review of chronic palmoplantar pustulosis interventions found no trials for methotrexate. 40 
Psoriatic arthropathy
Although widely accepted as effective, methotrexate has been shown to be effective for psoriatic arthritis in only one study using high doses administered parenterally in a systematic review of psoriatic arthropathy interventions. There is inconclusive evidence for the use of low-dose oral methotrexate. 41 
Adverse effects
Methotrexate use is associated with a large number of sideeffects and toxicity reactions. 43 Excretion is via the kidney and drug levels are therefore affected by renal function (Table XXII) . 
Folic acid supplementation
The use of folate supplementation to reduce side-effects is controversial. A systematic review of its use in rheumatoid arthritis (RA) could not show any benefit owing to lack of uniformity of outcome measures, but did support the protective effects of folate for gastro-intestinal tract (GIT) and mucosal side-effect reduction. The dose of folic acid or folinic acid did not appear to matter. 50 A recent randomised placebo-controlled study in RA patients (N=454) showed folate supplementation to be protective for hepatotoxicity compared with placebo, but it had no effect on GIT or mucosal symptoms. 51 Folate supplementation has been shown to compromise methotrexate efficacy. 52, 53 Concomitant use of folate increased the total dose of methotrexate necessary to achieve the same response when compared with methotrexate alone. 51, 53 
Alternative systemic therapies
Alternative systemic agents sometimes used for recalcitrant psoriasis management include hydroxyurea, sulfasalazine, azathioprine, mycophenolate mofetil, fumaric acid esters, 6-thioguanine and leflunomide. Only those that are available in South Africa for which there is supportive published evidence of efficacy from RCTs are included.
Hydroxyurea/hydroxycarbamide (Table XXIII)
Background Hydroxyurea (Hydrea ® ) is cytotoxic, inhibiting DNA synthesis. Its mechanism of action is unknown in psoriasis. It suppresses the bone marrow and is best regarded as teratogenic, but is not nephrotoxic or significantly hepatotoxic. 54, 55 Hydroxyurea has been proposed as a treatment for HIV because it inhibits DNA synthesis and causes cell cycle arrest and has favourable toxicity and drug interaction profiles. Laboratory work has shown that it blocks HIV transcription and/or replication and acts synergistically with didanosine in this regard.
56
Evidence of efficacy
Plaque psoriasis
A systematic review 36 reported one small RCT in which hydroxyurea (0.5 g twice daily) was compared with placebo in 10 patients with severe psoriasis in a 2×4-week cross-over 57 
Efficacy
Effective for recalcitrant psoriasis Lack of published evidence to support efficacy of hydroxyurea for palmoplantar psoriasis Lack of published evidence to support efficacy of hydroxyurea for psoriatic arthritis May have a role in the treatment of HIV-affected patients Important adverse reactions Use is associated with bone marrow suppression and the side-effects may develop months after starting treatment 54, 55 Macrocytosis is common and not necessarily associated with anaemiamay be seen within 24 hours of the first dose and is a good indicator of compliance 55, 57 Mucocutaneous side-effects: alopecia, skin, hair and nail discoloration, painful lower leg ulceration, dermatomysitis and drug-induced lupus (longterm use) 54, 55 There is a risk of malignancies (cutaneous, leukaemia transformation) 54, 55 Acute toxicity Acute mucocutaneous toxicity causes intense acral erythema and oedema, generalised pigmentation and stomatitis 54, 55, 57 Important drug interactions Predominantly drugs causing myelosuppression Level of evidence 1-Strength of recommendation C
Therapeutic recommendation
• Methotrexate is effective for chronic moderate to severe plaque psoriasis.
• Methotrexate has been shown to:
• Be effective for moderate to severe plaque psoriasis when used at doses of 7.5 -25 mg/wk
• Have equivalent but varying efficacy compared with ciclosporin, dependent on the population and dose studied and the use of folate supplementation
• Not be as effective as adalimumab and to cause more adverse events.
• There are no trials of methotrexate efficacy for palmoplantar pustular psoriasis.
• Methotrexate may be effective for psoriatic arthritis.
• Methotrexate use is limited by the side-effect and contraindication profile and monitoring required while on use.
• Folate supplementation may reduce hepatotoxicity side-effects in psoriatic patients, but can compromise methotrexate efficacy.
study. Improvement was noted by both patients and doctors during periods of active therapy (9/10) compared with placebo (1/10).
A review of the use of hydroxyurea for psoriasis 55 identified a preliminary report of a small RCT comparing hydroxyurea (1 g/d) with methotrexate (2.5 mg/d) in 8 patients in a 2×6-week cross-over study. Hydroxyurea was reported to be as effective as, or better than, methotrexate in 5/8 patients.
Two open-label case series summarised in the British Association of Dermatology guidelines 54 and the above review 55 reported that >60% of the 60 and 85 patients treated with hydroxyurea, respectively, achieved a good or excellent response (38/60 achieved 60 -80% clearance, 10/60 no response; 51/85 clear or almost clear, 6/80 no response). Doses of hydroxyurea and treatment period varied (1 g/d over 4 -12 weeks, repeated over 18 months; 0.5 g/d increased to 1.5 g/d in poor responders over 4 -36 months). Responses were seen within the first 6 weeks of therapy and the response was maintained on therapy. Remission was seen for all forms of psoriasis including pustular and erythrodermic psoriasis. Additional case series were identified in the review. 55 In 100 patients managed with hydroxyurea (1 g/d treated for variable periods over 8 years) a 'worthwhile' response was seen in 63/100 patients including the 18 'excellent' responses. Two smaller series (20 and 16 patients) reported similar good response rates.
An open-label study of 31 chronic plaque psoriasis patients in India reported a good, but slow, response for hydroxyurea dosed at 1.0 g -1.5 g/d. Treatment duration ranged from 6 to 136 weeks. Good responses (70 -90% reduction in PASI) were reported for 17/31 (53%) with complete or almost complete (>90% reduction in PASI) responses seen in 8/31 (16%). Macrocytosis was seen in all patients by 2 weeks and all adverse effects were reported as mild and reversible. 57 The German guidelines did not include hydroxyurea. 33 
Pustular psoriasis
A systematic review of chronic palmoplantar pustulosis interventions found 1 small (13 patients), short, cross-over trial comparing hydroxyurea with placebo. There were no differences in the scores during the placebo and intervention period. 40 
Psoriatic arthropathy
A systematic review of chronic psoriatic arthritis interventions found no trials for hydroxyurea efficacy that could be evaluated. 41 
Adverse effects
Adverse effects of hydroxyurea are set out in Table XXIII. (Table XXIV) Background Sulfasalazine (Salazopyrin ® ) is an anti-inflammatory agent used widely for treating inflammatory joint disease. It is split by intestinal bacteria into sulfapyridine and 5-aminosalicylic acid. Sulfapyridine is absorbed, metabolised in the liver and excreted in the kidney. The 5-aminosalicylic acid is excreted in the faeces. Its mechanism of action is unknown in psoriasis. It is potentially a bone marrow suppressant.
Sulfasalazine
36
Evidence of efficacy
Plaque psoriasis
A systematic review 36 revealed one small RCT in which sulfasalazine (3 -4 g/d) was compared with placebo in 50 patients with plaque psoriasis over 8 weeks. Improvement (>60%) was noted in 7/17 (41%) of those treated who were assessable, compared with none of those receiving placebo (0/27). Six of the original 23 patients withdrew because of sideeffects.
The British Association of Dermatologists 53 and German guidelines 33 did not include sulfasalazine.
Pustular psoriasis
A systematic review of chronic palmoplantar pustulosis interventions did not report any studies for sulfasalazine use. 40 
Psoriatic arthropathy
A systematic review of chronic psoriatic arthritis interventions found 6 trials evaluating sulfasalazine efficacy meeting their criteria for inclusion. 41 They conclude that there is good published efficacy for sulfasalazine use for treating psoriatic arthritis, despite a significant placebo response for the condition.
Adverse effects
Adverse effects are set out in Table XXIV.
Biologicals
Overview and background information
Although effective, the conventional systemic drugs including methotrexate, ciclosporin and retinoids are associated with considerable toxicity that limits their long-term use. Recent developments in more targeted therapies involving biological
Therapeutic recommendation
• Hydroxyurea has been shown to be effective as a systemic agent at doses of 0.5 -1.5 g/d for recalcitrant psoriasis.
• There is a lack of evidence to support efficacy of hydroxyurea for palmoplantar pustular psoriasis.
• There are no trials of hydroxyurea use for psoriatic psoriasis.
• Hydroxyurea may have a role in treating HIV-affected patients.
• Macrocytosis is commonly seen and a marker of compliance.
• There is little evidence to support the efficacy of sulfasalazine for psoriasis of the skin.
• Sulfasalazine may have a role in treating psoriasis patients with psoriatic arthritis.
agents, such as anti-T-cell agents and inhibitors of tumour necrosis factor-alpha (TNF-α), offer an alternative treatment approach with the possibility of longer continuous therapy, which may translate into disease control and improved quality of life.
Biological agents are proteins that can be extracted from animal tissue or produced by recombinant DNA technology and possess pharmacological activity. 58 Biological therapies block specific molecular steps in the pathogenesis of psoriasis. Three types of molecules have been studied for use in psoriasis:
• recombinant human cytokines or growth factors
• monoclonal antibodies
• fusion proteins.
The nomenclature of biologicals has been standardised, and the suffix of the drug name helps with identification (Table  XXV) .
Strategies for biological therapy in psoriasis
Biologicals used to treat psoriasis target two key steps in the pathogenesis of the disease, namely either:
• T-cell or antigen-presenting cell targeted (e.g. efaluzimab, alefacept), or
• acting on TNF-α (e.g. adalumimab, etanercept, infliximab).
Considerations for biological therapy
In considering a patient for biological therapy, the following assessment tools are used:
• PASI
59
• DLQI
58
• BSA affected.
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The BSA is used where PASI is not applicable, e.g. in pustular psoriasis.
Eligibility criteria
To be considered for treatment, patients:
• must have severe disease, and
• must fulfil one of the clinical categories outlined in (ii) below.
(i) Definition of severe disease:
• PASI score ≥10
• or BSA of ≥10% if PASI is not applicable
• disease should be severe for more than 6 months
• disease should be resistant to therapy
• patient should be a candidate for systemic therapy.
In some circumstances, e.g. disabling acral disease, patients may fall outside this definition but may still be considered for treatment.
(ii) At least one of the following clinical categories must be fulfilled.
Patients who:
• have developed or are at higher than average risk of developing clinically important drug-related toxicity and where alternative standard therapy cannot be used
• are or have become intolerant to or cannot receive standard systemic therapy
• are or have become unresponsive to standard therapy
• have disease that is only controlled by repeated inpatient management
• have significant, co-existent, unrelated co-morbidity that precludes use of systemic agents such as ciclosporin or methotrexate
• have severe, unstable, life-threatening disease (erythroderma or pustular psoriasis) Receptor-antibody fusion protein (alefacept, etanercept, onercept, etc.)
• have psoriatic arthritis fulfilling the South African Rheumatology Society eligibility criteria for treatment with anti-TNF agents in association with skin disease.
Standard systemic therapy includes:
• acitretin
• ciclosporin
• methotrexate
• narrow-band ultraviolet (UV) B
• PUVA.
Unresponsive to standard therapy is defined as an unsatisfactory clinical response (less than 50% improvement in baseline PASI score or percentage BSA where PASI is not applicable, and less than 5-point improvement in DLQI) to at least 3 months of treatment in the therapeutic dose range to the following treatments:
• methotrexate single weekly dose (oral, subcutaneous, intramuscular) 15 mg, max. 25 -30 mg
• acitretin 25 -50 mg/d
• ciclosporin 2.5 -5 mg/kg/d
• narrow-band UVB or PUVA (non-response, rapid relapse or exceeding recommended maximum doses) 150 -200 treatments for PUVA and 350 treatments for narrow-band UVB.
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A DLQI score of >10 correlates with a substantial effect on the patient's quality of life.
Exclusion criteria for anti-TNF agents and efalizumab
• Pregnant or breastfeeding.
• Active infections. High risk includes the following:
• chronic leg ulcers
• persistent or recurrent chest infections
• indwelling urinary catheter
• latent tuberculosis.*
• Malignancy or premalignancy states excluding:
• adequately treated non-melanoma skin cancer
• malignancies diagnosed and treated more than 10 years previously.
• Demyelinating disease.*
• Congestive cardiac failure.*
Relative contraindications
• PUVA therapy >200 treatments, especially when followed by ciclosporin therapy
• HIV positive or AIDS
• hepatitis B or C.
Adequate response to treatment
This is defined as a 50% or greater reduction in baseline PASI score (or percentage BSA where PASI is not applicable) and a 5-point or greater improvement in DLQI within 3 months of initiation of treatment.
Withdrawal of therapy
Therapy should be withdrawn if the criteria for adequate response have not been fulfilled in 3 months.
Who should prescribe biological therapy?
Treatment should be initiated and monitored (Table XXVI) by consultant dermatologists experienced in managing difficult psoriasis.
*These apply to anti-TNF agents only. 
Comment:
Tuberculin skin testing may be unreliable in patients who are immunocompromised. Clinical awareness of the possibility of TB should be maintained throughout anti-TNF therapy and for 6 months after cessation. A new diagnostic test that assays interferon-gamma to identify TB is not any better than the Mantoux test as neither is capable of differentiating between latent and active disease. Table XXVII .
General assessment
The efficacy of alefacept as induction therapy has been demonstrated in placebo-controlled studies, with 28% of patients achieving PASI-75 after a 12-week course (7.5 mg administered intravenously once weekly), rising to 40% in those patients receiving a second treatment course. 63 Intramuscular alefacept (10 or 15 mg once weekly) demonstrated PASI-75 in 28 -33% of patients after 12 weeks. Data for longer treatment with alefacept are based on reports of repeated 12-week treatment courses. 63 Follow-up data from both phase III studies showed that after one course of therapy, 29% of patients achieved PASI-75. Among patients who received at least two courses of alefacept, an incremental response was seen with 54% achieving PASI-75. 63 For patients who responded, remission lasted an average of 7 months. Continuous treatment is not prescribed in clinical practice; rather, alefacept is given as intermittent 12-week treatment courses, either as monotherapy or in combination with other agents. 63 Alefacept is generally well tolerated. Chills are occasionally experienced, particularly with IV administration and usually soon after dosing, and are often limited to one or two occasions during early treatment. It is necessary to monitor CD4+ cell counts before and during alefacept therapy, 63 and the drug should be withheld if the CD4 count drops below 250 cells/µl and discontinued if it remains below 250 cells/µl for 4 consecutive weeks. 64 However, randomised controlled studies do not reveal a higher incidence of infections and opportunistic infections. The rate of malignancies was similar to the control group. 65 
Efalizumab
A press release dated 19 In the UK adalimumab was licensed for the treatment of RA in September 2003. It is registered in South Africa for the treatment of psoriasis and psoriatic arthritis, and is also licensed for the treatment of other inflammatory conditions such as Crohn's disease, RA and ankylosing spondylitis. 68 Early evidence indicated that PASI-75 can be achieved in 53% of patients after 12 weeks' treatment. More recent evidence shows that PASI-75 can be achieved in 71% of patients by 16 weeks. 69 Recent published data, the first head-to-head trial evaluating the comparative efficacy of biological versus conventional systemic treatment for psoriasis, demonstrated significantly higher efficacy of adalimumab compared with methotrexate; 80% of patients receiving adalimumab and 36% of patients receiving methotrexate achieved PASI-75 after 16 weeks. 63 Data for the treatment of RA suggest that adalimumab is as efficacious as infliximab or etanercept, but no head-to-head trials have been conducted. 70 Compared with other biological agents, longer-term efficacy data for adalimumab are more limited. In the larger phase 65, 66 Often sustained remission. Prior response to alefacept is a likely marker of future treatment response; patients responding to the first course of therapy may therefore be treated long term with repeated 12-week courses of alefacept at a minimum of 24-week intervals 13 Improved outcome with second course of treatment and consistent benefit of repeated administration 13 Level of evidence 1 13 Strength of recommendation A 13 Other In phase II trials for psoriatic arthritis III study, among patients reaching PASI-75 after treatment with adalimumab, a loss of response was observed following re-randomisation to placebo, suggesting that continuous treatment is necessary to maintain a response. 69 In this study, after 24 weeks of continuous treatment, 70% of patients achieved PASI-75, and at 33 weeks 89% achieved this response. However, PASI scores for longer treatment duration were not reported.
In an open-label extension to the initial phase II study, in which 106 patients received continued treatment for 60 weeks, PASI-75 was achieved by 64% of patients receiving continuous weekly dosing and by 56% receiving adalimumab every other week. 70 Safety data for adalimumab in psoriasis are also limited compared with other biological agents. The most commonly reported adverse events in patients treated with adalimumab were nasopharyngitis, upper respiratory tract infection and headache. However, the incidence of severe adverse events was low and comparable in the adalimumab and placebo treatment groups. Until more data are available, the caveats for use of adalimumab should be considered to be the same as those for other TNF-α blockers. 63 
Etanercept
Etanercept (Enbrel ® , Wyeth Pharmaceuticals) is a fully human soluble recombinant p75 TNF receptor that blocks the binding of TNF to cell surface receptors, thereby neutralising its biological activity.
The dose regimen, precautions and clinical response are summarised in Table XXIX .
General assessment
Etanercept is registered in South Africa for the treatment of psoriasis and psoriatic arthritis. It is also licensed for the treatment of other inflammatory conditions such as RA, juvenile chronic arthritis and ankylosing spondylitis. 71 The recommended dose of etanercept for the treatment of psoriasis is 25 mg subcutaneously twice weekly by selfadministration, although this may be increased to 50 mg twice weekly. Etanercept may be given for up to 24 weeks.
PASI-75 was achieved in up to 34% of patients after 12 weeks of treatment with 25 mg subcutaneous etanercept twice weekly. Continuing treatment for 24 weeks further increased response. Doubling the dose to 50 mg twice weekly achieved PASI-75 in up to 49% of patients at 12 weeks. 72, 73 The median time to relapse after cessation of treatment was approximately 3 months, with no rebound observed.
Etanercept treatment response has been found to be dose dependent, with a greater proportion of patients achieving PASI-75 with the 50 mg twice-weekly dosing regimen than with the 25 mg twice-weekly regimen over 12 weeks. Extending treatment to 24 weeks also improves response, with 44 -45% of patients achieving PASI-75 with the 25 mg twice-weekly regimen, and 59% with the 50 mg twice-weekly regimen. 63 Longer-term data for up to 60 Other Approved for the treatment of psoriatic arthritis Etanercept has been used in children aged 4 -17 years with plaque psoriasis. Doses of 0.8 mg/kg to a maximum of 50 mg were given once weekly, and 57% achieved PASI-75 compared with 11% of those on placebo. 74 Etanercept has been well tolerated in clinical trials, apart from mild injection site reactions occurring in up to 36% of patients; these rarely led to discontinuation of treatment. 75 Neutralising antibody formation could not be observed. There are concerns about increased infection rates and a risk of malignancy associated with the use of etanercept. However, a safety review in RA showed a similar rate of serious infections for etanercept-and placebo-treated patients. No opportunistic infections were observed and the incidence of malignancies was similar to that expected. Table XXX .
Infliximab is registered in South Africa for the treatment of psoriasis and psoriatic arthritis. It is also licensed for the treatment of other inflammatory conditions such as Crohn's disease in adults and children, ulcerative colitis, RA and ankylosing spondylitis. 77 The efficacy of infliximab in psoriasis has been demonstrated in two phase II studies and a subsequent larger phase III study (EXPRESS study), involving a total of 660 patients, which found that treatment with infliximab (administered intravenously in doses of 3, 5 or 10 mg at weeks 0, 2 and 6) resulted in achievement of PASI-75 after 10 weeks in 70 -80% of patients. Rapid clinical improvements were observed in all three studies. 63, 78 Longer-term data from the EXPRESS study have been reported, with treatment continued (as an intravenous infusion of 5 mg/kg) at weeks 0, 2 and 6, and then every 8 weeks through to week 46. Of 271 patients receiving continued infliximab, a sustained response was observed at week 24, with 82% of patients attaining PASI-75, after which a moderate reduction in efficacy was noted, falling to 61% of patients reaching PASI-75 at week 50. 63 Similar findings were reported in a more recent comparison of continuous and intermittent infliximab therapy over 1 year, which involved an initial 835 patients. 33 In an initial placebocontrolled induction phase of this study, in the active treatment arm (intravenous infusions of 3 or 5 mg/kg) at weeks 0, 2 and 6, PASI-75 was achieved in 70% (3 mg/kg) and 75% (5 mg/kg) of patients. 63 Patients were then randomised to receive continuous treatment (as intravenous infusions every 8 weeks) or intermittent 'as-needed' dosing (given when a PASI-75 response was lost). With continuous therapy up to week 26, PASI-75 scores were maintained in 64% (3 mg/kg) and 78% (5 mg/kg) of patients. Subsequently, a reduced response to continuous 8-weekly infusion therapy was observed, with PASI-75 achieved by 44% of patients (3 mg/kg) and 54% of patients (5 mg/kg) at week 50. Patients receiving continuous dosing had consistently higher PASI-75 scores than those treated with intermittent dosing, and PASI scores were greater with the higher dose of infliximab. 63 These data suggest that infliximab is effective as continuous treatment for up to 1 year, with some loss of response over time. Its benefits beyond this time frame are not known owing to the lack of longer-term data. 63 Infliximab has been well tolerated in clinical trials, with safety data available from over 1 million patients treated with the drug for various inflammatory conditions. 79 More commonly observed adverse events include headaches, nausea, upper respiratory infections and infusion reactions. Infusion reactions occurred in up to 16% of patients, but only 2% discontinued the treatment because of the reactions. 80 There have been reports of new or worsening congestive cardiac failure in patients treated with infliximab and it should therefore be used with caution in patients with pre-existing cardiac failure. 81 In a small number of patients with Crohn's disease or RA, infections, antinuclear antibody formation and drug-induced auto-immune disease have been reported. 82, 83 Patient-years of infliximab usage are associated with more reports of opportunistic infections, including tuberculosis, than other anti-TNF agents. There have also been rare reports of demyelinating disease. 84 All patients considered for treatment with infliximab should be screened for active infection, in particular tuberculosis. There is currently no indication of higher rates of malignancy in patients treated with infliximab, but long-term data are not yet available. There Level of evidence 1 13 Strength of recommendation A 13 Other Effective for psoriatic arthritis is concern about an increased risk of lymphoma, particularly in patients with RA, who appear to be more susceptible. 80 In patients with psoriasis who receive TNF-α blockers, long-term pharmacovigilance is required for skin cancer, as a significant number of these patients with severe disease will have also received photochemotherapy (PUVA). Ustekinumab (Stelara®, Janssen Pharmaceuticals) is a fully human monoclonal antibody, which targets the p40 subunit of IL-12 and IL-23. The presumed mechanism of action is to block the binding of IL-12 and IL-23 to receptors on undifferentiated T cells, preventing differentiation/clonal expansion of pathogenic Th1 and Th17 populations and subsequent downregulation of inflammatory cytokines. 85 The dosage regimen, precautions and clinical response are summarised in Table XXXI .
Members of the IL-12p40 family, namely IL-12 and IL-23, have been shown to play a pro-inflammatory role in psoriasis. They are produced by activated antigen-presenting cells and have been shown to increase interferon-gamma synthesis by T cells. IL-23 acts preferentially on interferon gamma production by memory T cells. IL-12 also increases differentiation of naive TH0 to TH1 cells and increases the cytolytic activity of activated T cells and NK cells. 86 In the European Union, ustekinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, have a contraindication to or are intolerant to other systemic therapies, including ciclosporin, methotrexate and PUVA. 85 In an open-label, phase I study of a single infusion of anti-IL12p40 (ustekinumab), PASI-75 was achieved by 67% of patients between 8 and 16 weeks after administration of the agent, and in the higher-dose group 100% of patients achieved PASI-75. 87 88 Recent evidence from another phase III study (PHOENIX II) in patients with moderate to severe psoriasis demonstrated a maintained treatment response at week 40, with between 58% and 67% of patients achieving PASI-75 at lower (45 mg) and higher (90 mg) dosages, respectively. 89 Serious adverse events occurred in 4% of patients who received the monoclonal antibody and in 1% of those who received placebo. This study demonstrates the therapeutic efficacy of an IL-12/23 monoclonal antibody in psoriasis and provides evidence for a role of IL-12/23 in the pathophysiology of psoriasis. 13 A recent phase II study in patients with psoriatic arthritis, of whom 85% had associated skin psoriasis, showed that treatment with ustekinumab (90 mg or 63 mg) given weekly (weeks 0 -3) followed by placebo at weeks 12 and 16, demonstrated an ACR 20 response of 42% for joint disease and a PASI-75 of 52% for skin disease. In this study ustekinumab treatment reduced the signs and symptoms of arthritis and associated psoriatic skin lesions, as well as significantly improving physical disability and quality of life in the majority of patients. This response was maintained in the majority of patients over week 36, after the last ustekinumab injection at week 3. 90 No rebound response was reported in this study. 90 Infections such as tuberculosis are less likely with ustekinumab than with other biologicals, but latent infection should be actively excluded.
Comparative short-term efficacy of the biologicals
Two recent meta-analyses have been performed to summarise clinical trial efficacy data enabling a quantitative, indirect comparison between agents, as no current direct 'head-to-head' data between biological agents are available. 47, 91 In the first meta-analysis, 16 randomised, controlled, doubleblind, monotherapy trials of alefacept (N=3), efalizumab (N=5),
Table XXXI. Ustekinumab (no data)
Recommended dose
The recommended initial dosage of ustekinumab is 45 mg administered subcutaneously at week 0, followed by a 45 mg dose at week 4, then every 12 weeks thereafter 85 For patients with a body weight >100 kg the dose is 90 mg administered subcutaneously at week 0, followed by a 90 mg dose at week 4, then every 12 weeks thereafter In patients weighing >100 kg, 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these patients 85 Consideration should be given to discontinuing treatment in patients who have shown no response up to 28 In the second meta-analysis 24 RCTs totalling 9 384 patients were analysed qualitatively. Sixteen double-blind placebocontrolled trials were eligible for meta-analysis. Efficacy was defined as proportion of participants who had achieved PASI-75 at primary efficacy measurement (week 8 -16). Infliximab was significantly superior to all other interventions (RD 77%, 95% CI 72 -81%). Adalimumab (RD 64%, 95% CI 61 -68%) was superior to ciclosporin (RD 33%, 95% CI 13 -52%), etanercept 50 mg twice weekly (RD 44%, 95% CI 40 -48%) and etanercept 25 mg twice weekly (RD 30%, 95% CI 25 -35%). 47 Additionally, a recent poster presentation of a phase III trial (ACCEPT) comparing the efficacy of ustekinumab and etanercept in moderate to severe psoriasis demonstrated that a significantly greater proportion of patients achieved PASI-75 with ustekinumab 45 mg (67.5%, p=0.012) and 90 mg (73.8%, p<0.001) given at weeks 0 and 4 than with etanercept (56.8%) given as 50 mg twice weekly. 92 Ustekinumab has also been compared in a meta-analysis versus the other biological treatments in a recent poster presentation. The estimated mean PASI-75 responses were as follows: infliximab (mean 80%, 95% CI 70 -87%), ustekinumab 90 mg (74%, 68 -80%), ustekinumab 45 mg (69%, 62 -75%), adalimumab (58%, 49 -68%), etanercept 50 mg twice weekly (52%, 45 -59%), etanercept 25 mg twice weekly (39%, 30 -48%) and supportive care/placebo (4%, 3 -4%). 93 
Areas for future research
The main research gaps remain the great lack of key comparative data and of data concerning the long-term safety and efficacy of biological and non-biological treatments for moderate to severe psoriasis. Additionally, pragmatic headto-head RCTs lasting at least 2 years are needed to compare different biologicals with each other and with conventional systemic treatments for psoriasis. Because biologicals are currently recommended for patients who fail to respond to conventional systemic treatments, the comparative efficacy of biologicals in such a subgroup of treatment failures has to be assessed. 63 
Choice of agents
The choice of which of the biological agents to use is based on the clinical pattern of psoriasis, pre-existing co-morbidities, patient preference and local facilities. 62 A separate recommendation guideline for the use of biologicals in psoriasis is currently underway, and will further clarify the choice of biological agent, based on the most recently available research and clinical data. In the interim readers are requested to refer to the British Association of Dermatologists guidelines or consult the Dermatological Society of South Africa website.
